ReviewInternational ophthalmology2025
Bevacizumab and beyond: investigating the role of combination therapies in the management of retinal diseases.
Review in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To provide a narrative overview of the latest laboratory studies and clinical trials investigating the combination of bevacizumab with various supplements, including vitamin D, anti-oxidants, and other intravitreal injectable agents. We examine the potential benefits of these combinations in reducing vascular endothelial growth factor (VEGF) levels, improving clinical outcomes, and enhancing the overall treatment of retinal diseases. Bevacizumab, a widely used anti-VEGF agent, has demonstrated significant clinical benefits in the treatment of these retinal disorders by inhibiting abnormal blood vessel growth and reducing retinal edema. However, its use is associated with several limitations, including intraocular inflammation, systemic side effects, variability in patient responses, and the potential for drug resistance. To overcome these limitations, adjunctive treatment regimens may be necessary to enhance the efficacy and safety of bevacizumab. The retina, as one of the most metabolically active tissues in the body, is highly susceptible to hypoxia, leading to retinal ischemia and subsequent VEGF production. By exploring the synergies between bevacizumab and these supplements, we hope to identify novel therapeutic strategies that can improve patient outcomes and address the unmet needs in the management of retinal disorders.
Indexed as
Identifiers
41128807What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.